Comparative analysis of the differences between dacomitinib and dacomitinib

Dacomitinib and dacomitinib (Dacomitinib) actually refer to the same drug. The only difference between the two is the translation of the Chinese name, which is the result of different translation methods. The English name "Dacomitinib" is the international generic name of this drug, while "Dacomitinib" and "Dacomitinib" are both used in Chinese medical literature, among which "Dacomitinib" is more commonly seen in official domestic drug registrations and instructions.

Dacomitinib is an oral, irreversible pan-HER inhibitor, mainly used to treat patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). Its mechanism of action is by irreversibly binding and inhibiting HER1 (EGFR), HER2 and HER4 receptors, thereby blocking the signaling pathways of cancer cells and inhibiting their growth and spread. The drug was approved by the FDA in 2018 and has subsequently been approved in many countries and regions.

In China, the drug has been officially launched as “dacomitinib” and has been included in the national medical insurance directory. First-line treatment for patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR sensitizing mutations. Compared with the first-generation EGFR-TKI (such as gefitinib), clinical studies of dacomitinib have shown that it has certain advantages in terms of progression-free survival (PFS) and overall survival (OS), especially in patients with brain metastases.

In summary, "Dacomitinib" and "Dacomitinib" are different names for the same drug. Their English names are both Dacomitinib, which belong to the second generation EGFR-TKI targeted drugs and are used for the treatment of specific types of non-small cell lung cancer. When selecting and using this drug, the key is to pay attention to its clinical indications, efficacy, safety and medical insurance coverage, without getting hung up on the difference in name.

Reference: https://go.drugbank.com/drugs/